FDA advisers backed Replimune’s RP1 melanoma therapy, bringing the investigational skin cancer drug closer to approval for advanced melanoma.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.